Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:LIFE)

1.900 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
The Latest Analyst Ratings for aTyr Pharma
Via Benzinga
aTyr Pharma: Q1 Earnings Insights
Via Benzinga
3 Stocks and Cryptos With the Highest Potential Returns
If you're only worried about upside, these stocks and cryptos have some of the highest possible returns in the market. 
Via InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Where aTyr Pharma Stands With Analysts
Via Benzinga
aTyr Pharma's Earnings: A Preview
Via Benzinga
aTyr Pharma: Q2 Earnings Insights
  aTyr Pharma (NASDAQ:LIFE) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
This Company Is Beginning A Pivotal Phase 3 EFZO-FIT™ Study. Could It Be A Much-Needed Treatment For Pulmonary Sarcoidosis?
Most people may never have heard of sarcoidosis, an inflammatory disease that affects about 1.2 million people worldwide.  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
Beat Of Life Entertainment- A One Stop Solution For Internet Marketing
Internet marketing is the solution for business development in the digitalization era. 
Via IssueWire
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
A Preview Of aTyr Pharma's Earnings
  aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma... 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Snap to $25? Plus This Analyst Cuts Price Target On Amazon.com
Keybanc cut the price target for Snap Inc. (NYSE: SNAP) from $27 to $25. Snap is scheduled to release its second-quarter results after the closing bell on Thursday. Snap shares rose 0.3% to $15.55 in... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded higher this morning on Thursday after closing slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Earnings Outlook For aTyr Pharma
aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that aTyr Pharma will... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback